Page 4 - Diabetes

One-fifth of Indians aged 45 and above had diabetes in 2019: Study

About a fifth of those aged 45 and above were living with diabetes in 2019, with two in every five possibly unaware of their condition, according to data from a study among India's ageing adults. Findings published in The Lancet Global Health also suggest that as the country's population rapidly ages, diabetes cases among the middle-aged and older adults will increase, even if increase in prevalence of the condition in age-specific groups can be arrested, authors said. Researchers, including those from the International Institute for Population Sciences, Mumbai, and US, also found that 46 per cent of those aware of their diabetes regained a control over blood sugar levels, while around 60 per cent were able to control their blood pressure the same year. Six per cent were taking a lipid-lowering medication to reduce the risk of cardiovascular disease, the team said. The 'Longitudinal Aging Study in India' (LASI), which surveyed about 60,000 adults aged 45 and above during 2017-2019

Weighty issues: India's rush to make weight-loss drugs demands user caution

The global market for weight-loss drugs is estimated at $100 billion by the end of the decade

7,000 steps a day - that's all it takes to outwalk heart disease, says study

A global study finds that walking 7,000 steps daily can significantly reduce the risk of death by heart disease, diabetes, dementia and more, offering a practical alternative to the 10,000-step target

Biocon Biologics expands diabetes portfolio with FDA approval for Kirsty

Interchangeable biosimilar to NovoLog in the US and will be available in prefilled pens and vials

From blood pressure to mental health, key health checks men must not skip

From blood pressure to mental health, these essential screenings help men detect silent health risks early and stay ahead of preventable chronic conditions

Muscle loss to cancer: Shubhanshu Shukla's mission targets health in space

Indian astronaut Shubhanshu Shukla is leading muscle loss, diabetes, brain activity, and cancer cell studies on the ISS-research that could benefit both space explorers and patients on Earth

Diabetes myths vs facts: 15 health risks you may be unknowingly taking

Fact-Check Friday: From the belief that fruits are bad to blaming sugar alone, doctors bust 15 widespread diabetes myths and offer clear, science-backed facts for better care

Why jamun seed powder is called a superfood for managing diabetes

Jamun seed powder contains jamboline and jambosine that help regulate blood sugar, support pancreatic function, and may aid in diabetes prevention if used correctly

Understanding gestational diabetes: Why early detection, awareness matter

Despite common misconceptions, gestational diabetes can affect healthy women of any age or body type. Often symptomless, it frequently goes undiagnosed-putting both mother and child at risk

Does your job involve meeting people? It may raise diabetes risk: Study

A 14-year study of nearly 3 million people found that emotional strain in public-facing roles may increase type 2 diabetes risk by up to 47 per cent

Stem cell breakthrough: New therapy raises hopes of curing type 1 diabetes

A new stem cell-based treatment helped most trial participants with severe type 1 diabetes stop insulin use, offering hope for long-term freedom from injections

Abbott, MSD join hands to distribute key diabetic drug across India

Abbott to distribute MSD's sitagliptin portfolio-Januvia, Janumet, Janumet XR-in India, targeting deeper reach in the ₹950-1,000 crore diabetes drug segment

That 'healthy' juice habit? It might be messing with your metabolism

Think juice is better than soda? A large new study shows even 100% fruit juice raises diabetes risk, urging people to eat whole fruits instead

Obesity injections may have less weight loss effect in reality: Study

Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose, a study in US patients has found. Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide (Zepbound and Mounjaro) are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar. The study, published in the Obesity Journal, examined the effects of anti-obesity injectables on weight reduction and blood sugar regulation (glycaemic control) in a real-world setting. "Our study shows that patients treated for obesity with semaglutide or tirzepatide lost less weight on average in a regular clinical setting compared to what is observed in randomised clinical trials," lead author Dr Hamlet Gasoyan, a researcher with the Cleveland Clinic, US, said. "According to our data, this could be explained by higher rates of discontinuation and lower

Eli Lilly's weight loss drug Mounjaro sales bulk up 60% on dosage upgrade

It logged value sales worth Rs 12.61 crore in May, compared to Rs 7.88 crore in April.

Lilly's obesity drug Mounjaro's sales rise 60% in India amid rising demand

The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies

Biocon gets CDSCO approval for generic diabetes medication 'Liraglutide'

Biotech firm Biocon on Tuesday said it has received approval from the government authorities for a generic diabetes medication. The company has received approval for its Liraglutide drug substance and its wholly-owned subsidiary Biocon Pharma has received approval for its Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge), from the Drugs Controller General of India (CDSCO). The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise, the company said in a regulatory filing. "The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes," Biocon CEO and MD Siddharth Mittal said. India has one of the highest number of people with diabetes globally, with ...

Novo Nordisk to launch weight-loss drug Wegovy in India ahead of schedule

Amid rising demand and Eli Lilly's Mounjaro launch, Novo Nordisk is advancing plans to introduce its obesity drug Wegovy in the Indian market

Can the '2 per 20' rule really help stabilise blood sugar without exercise?

Research shows that light walking for 2 minutes after every 20 minutes of sitting may significantly lower post-meal blood sugar levels

5 products to be launched in 18 mths, US insulin mkt share up: BBL MD & CEO

Achieving 15 per cent year-on-year growth, with nearly four biosimilars with $200 million in revenue, is a big feat, says Tambe